Flagship Harbor Advisors, LLC Blueprint Medicines Corp Transaction History

Flagship Harbor Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$92.08 - $124.48 $5,616 - $7,593	-61 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$48.11 - $82.22 $1,202 - $2,055	-25 Reduced 29.07%	61 $4,000
Q3 2019 Oct 22, 2019	BUY	$72.9 - $101.41 $2,187 - $3,042	30 Added 53.57%	86 $6,000
Q2 2019 Jul 22, 2019	BUY	$73.54 - $97.8 $4,118 - $5,476	56 New	56 $5,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Flagship Harbor Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Flagship Harbor Advisors, LLC with notifications on news.